CD20 (Clusters of Differentiation 20) inhibitors

Name
CD20 (Clusters of Differentiation 20) inhibitors
Accession Number
DBCAT005729
Description

Not Available

ATC Classification
Drugs
DrugDrug Description
RituximabA monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.
OfatumumabAn anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications.
ObinutuzumabAn antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.
Drugs & Drug Targets
DrugTargetType
RituximabB-lymphocyte antigen CD20target
OfatumumabB-lymphocyte antigen CD20target
ObinutuzumabB-lymphocyte antigen CD20target